Immunotherapy for Medulloblastoma: Current Perspectives

References

• Pollack IF, Agnihotri S, Broniscer A. Childhood brain tumors: current management, biological insights, and future directions. J Neurosurg Pediatr. 2019;23(3):261–273. doi:10.3171/2018.10.PEDS1837730835699
   PubMed Web of Science ®Google Scholar
• Sonabend AM, Ogden AT, Maier LM, et al. Medulloblasoma: challenges for effective immunotherapy. J Neurooncol. 2012;108(1):1–10. doi:10.1007/s11060-011-0776-122173741
   PubMed Web of Science ®Google Scholar
• Thurnher MM. 2007 World Health Organization classification of tumours of the central nervous system. Cancer Imaging. 2009;9(Spec No A):S1–S3. doi:10.1102/1470-7330.2009.9001
   Google Scholar
• Archer TC, Mahoney EL, Pomeroy SL. Medulloblastoma: molecular classification-based personal therapeutics. Neurotherapeutics. 2017;14(2):265–273. doi:10.1007/s13311-017-0526-y28386677
   PubMed Web of Science ®Google Scholar
• Packer RJ, Finlay JL. Chemotherapy for childhood medulloblastoma and primitive neuroectodermal tumors. Oncologist. 1996;1(6):381–393. doi:10.1634/theoncologist.1-6-38110388020
   PubMedGoogle Scholar
• Ostrom QT, Cioffi G, Gittleman H, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012–2016. Neuro Oncol. 2019;21(Supplement_5):v1–v100. doi:10.1093/neuonc/noz15031675094
   PubMed Web of Science ®Google Scholar
• Zeltzer PM, Boyett JM, Finlay JL, et al. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the children’s cancer group 921 randomized phase III study. J Clin Oncol. 1999;17(3):832–845. doi:10.1200/JCO.1999.17.3.83210071274
   PubMed Web of Science ®Google Scholar
• Ris MD, Packer R, Goldwein J, Jones-Wallace D, Boyett JM. Intellectual outcome after reduced-dose radiation therapy plus adjuvant chemotherapy for medulloblastoma: a children’s cancer group study. J Clin Oncol. 2001;19(15):3470–3476. doi:10.1200/JCO.2001.19.15.347011481352
   PubMed Web of Science ®Google Scholar
• Taylor RE, Bailey CC, Robinson K, et al. Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: the International Society of Paediatric Oncology/United Kingdom children’s cancer study group PNET-3 study. J Clin Oncol. 2003;21(8):1581–1591. doi:10.1200/JCO.2003.05.11612697884
   PubMed Web of Science ®Google Scholar
• Sayour EJ, Mitchell DA. Immunotherapy for pediatric brain tumors. Brain Sci. 2017;7(10)137.
   Web of Science ®Google Scholar
• Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803–820. doi:10.1007/s00401-016-1545-127157931
   PubMed Web of Science ®Google Scholar
• Cavalli FMG, Remke M, Rampasek L, et al. Intertumoral heterogeneity within medulloblastoma subgroups. Cancer Cell. 2017;31(6):737–754 e736. doi:10.1016/j.ccell.2017.05.00528609654
   PubMed Web of Science ®Google Scholar
• Gibson P, Tong Y, Robinson G, et al. Subtypes of medulloblastoma have distinct developmental origins. Nature. 2010;468(7327):1095–1099. doi:10.1038/nature0958721150899
   PubMed Web of Science ®Google Scholar
• Grammel D, Warmuth-Metz M, von Bueren AO, et al. Sonic hedgehog-associated medulloblastoma arising from the cochlear nuclei of the brainstem. Acta Neuropathol. 2012;123(4):601–614. doi:10.1007/s00401-012-0961-022349907
   PubMed Web of Science ®Google Scholar
• Hooper CM, Hawes SM, Kees UR, Gottardo NG, Dallas PB, Alsina B. Gene expression analyses of the spatio-temporal relationships of human medulloblastoma subgroups during early human neurogenesis. PLoS One. 2014;9(11):e112909. doi:10.1371/journal.pone.011290925412507
   PubMed Web of Science ®Google Scholar
• Northcott PA, Jones DT, Kool M, et al. Medulloblastomics: the end of the beginning. Nat Rev Cancer. 2012;12(12):818–834. doi:10.1038/nrc341023175120
   PubMed Web of Science ®Google Scholar
• Taylor MD, Northcott PA, Korshunov A, et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol. 2012;123(4):465–472. doi:10.1007/s00401-011-0922-z22134537
   PubMed Web of Science ®Google Scholar
• Wood GW, Morantz RA. In vitro reversal of depressed T-lymphocyte function in the peripheral blood of brain tumor patients. J Natl Cancer Inst. 1982;68(1):27–33.6172627
   PubMedGoogle Scholar
• Wood GW, Morantz RA. Depressed T lymphocyte function in brain tumor patients: monocytes as suppressor cells. J Neurooncol. 1983;1(2):87–94. doi:10.1007/BF001829536236289
   PubMedGoogle Scholar
• Yamasaki T, Handa H, Yamashita J, Namba Y, Hanaoka M. Characteristic immunological responses to an experimental mouse brain tumor. Cancer Res. 1983;43(10):4610–4617.6603902
   PubMed Web of Science ®Google Scholar
• Gerosa M, Amadori G, Semenzato C, et al. Immunobiology of paediatric intracranial tumours. A preliminary report. Acta Neurochir (Wien). 1979;50(1–2):49–54. doi:10.1007/BF01813548316267
   PubMed Web of Science ®Google Scholar
• Gerosa MA, Amadori G, Semenzato P, Gasparotto G, Carteri A. Immunobiology of primary CNS tumors in infancy and childhood. B- and T-cell dependent immunity and cytotoxicity and cell kinetic evaluation. Childs Brain. 1980;6(2):92–102. doi:10.1159/0001198906965475
   PubMedGoogle Scholar
• Mitchell DA, Cui X, Schmittling RJ, et al. Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans. Blood. 2011;118(11):3003–3012. doi:10.1182/blood-2011-02-33456521768296
   PubMed Web of Science ®Google Scholar
• Mitchell DA, Batich KA, Gunn MD, et al. Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature. 2015;519(7543):366–369. doi:10.1038/nature1432025762141
   PubMed Web of Science ®Google Scholar
• Batich KA, Swartz AM, Sampson JH. Preconditioning vaccine sites for mRNA-transfected dendritic cell therapy and antitumor efficacy. Methods Mol Biol. 2016;1403:819–838.27076169
   PubMedGoogle Scholar
• Sampson JH, Maus MV, June CH. Immunotherapy for brain tumors. J Clin Oncol. 2017;35(21):2450–2456. doi:10.1200/JCO.2017.72.808928640704
   PubMed Web of Science ®Google Scholar
• Hao C, Tian J, Liu H, Li F, Niu H, Zhu B. Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: a systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2017;96(26):e7325. doi:10.1097/MD.000000000000732528658143
   PubMed Web of Science ®Google Scholar
• Alizadeh AA, Aranda V, Bardelli A, et al. Toward understanding and exploiting tumor heterogeneity. Nat Med. 2015;21(8):846–853. doi:10.1038/nm.391526248267
   PubMed Web of Science ®Google Scholar
• Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415–421. doi:10.1038/nature1247723945592
   PubMed Web of Science ®Google Scholar
• Fontebasso AM, Gayden T, Nikbakht H, et al. Epigenetic dysregulation: a novel pathway of oncogenesis in pediatric brain tumors. Acta Neuropathol. 2014;128(5):615–627. doi:10.1007/s00401-014-1325-825077668
   PubMed Web of Science ®Google Scholar
• Pham CD, Flores C, Yang C, et al. Differential immune microenvironments and response to immune checkpoint blockade among molecular subtypes of murine medulloblastoma. Clin Cancer Res. 2016;22(3):582–595. doi:10.1158/1078-0432.CCR-15-071326405194
   PubMed Web of Science ®Google Scholar
• Schlager C, Korner H, Krueger M, et al. Effector T-cell trafficking between the leptomeninges and the cerebrospinal fluid. Nature. 2016;530(7590):349–353. doi:10.1038/nature1693926863192
   PubMed Web of Science ®Google Scholar
• Kipnis J. Multifaceted interactions between adaptive immunity and the central nervous system. Science. 2016;353(6301):766–771. doi:10.1126/science.aag263827540163
   PubMed Web of Science ®Google Scholar
• Hu X, Deng Q, Ma L, et al. Meningeal lymphatic vessels regulate brain tumor drainage and immunity. Cell Res. 2020. doi:10.1038/s41422-020-0287-8
   Web of Science ®Google Scholar
• Woroniecka K, Chongsathidkiet P, Rhodin K, et al. T-cell exhaustion signatures vary with tumor type and are severe in glioblastoma. Clin Cancer Res. 2018;24(17):4175–4186. doi:10.1158/1078-0432.CCR-17-184629437767
   PubMed Web of Science ®Google Scholar
• Weller M, Butowski N, Tran DD, et al. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international Phase 3 trial. Lancet Oncol. 2017;18(10):1373–1385. doi:10.1016/S1470-2045(17)30517-X28844499
   PubMed Web of Science ®Google Scholar
• Mueller S, Chang S. Pediatric brain tumors: current treatment strategies and future therapeutic approaches. Neurotherapeutics. 2009;6(3):570–586. doi:10.1016/j.nurt.2009.04.00619560746
   PubMed Web of Science ®Google Scholar
• Packer RJ, Gajjar A, Vezina G, et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol. 2006;24(25):4202–4208. doi:10.1200/JCO.2006.06.498016943538
   PubMed Web of Science ®Google Scholar
• Merchant TE, Kun LE, Krasin MJ, et al. Multi-institution prospective trial of reduced-dose craniospinal irradiation (23.4 Gy) followed by conformal posterior fossa (36 Gy) and primary site irradiation (55.8 Gy) and dose-intensive chemotherapy for average-risk medulloblastoma. Int J Radiat Oncol Biol Phys. 2008;70(3):782–787. doi:10.1016/j.ijrobp.2007.07.234217892918
   PubMed Web of Science ®Google Scholar
• Gajjar A, Chintagumpala M, Ashley D, et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol. 2006;7(10):813–820. doi:10.1016/S1470-2045(06)70867-117012043
   PubMed Web of Science ®Google Scholar
• Wahba HA, Abu-Hegazy M, Wasel Y, Ismail EI, Zidan AS. Adjuvant chemotherapy after reduced craniospinal irradiation dose in children with average-risk medulloblastoma: a 5-year follow-up study. J BUON. 2013;18(2):425–429.23818356
   PubMed Web of Science ®Google Scholar
• Packer RJ, Goldwein J, Nicholson HS, et al. Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: a children’s cancer group study. J Clin Oncol. 1999;17(7):2127–2136. doi:10.1200/JCO.1999.17.7.212710561268
   PubMed Web of Science ®Google Scholar
• Tamburrini G, Frassanito P, Chieffo D, Massimi L, Caldarelli M, Di Rocco C. Cerebellar mutism. Childs Nerv Syst. 2015;31(10):1841–1851. doi:10.1007/s00381-015-2803-626351234
   PubMed Web of Science ®Google Scholar
• Merchant TE, Kiehna EN, Li C, et al. Modeling radiation dosimetry to predict cognitive outcomes in pediatric patients with CNS embryonal tumors including medulloblastoma. Int J Radiat Oncol Biol Phys. 2006;65(1):210–221. doi:10.1016/j.ijrobp.2005.10.03816472938
   PubMed Web of Science ®Google Scholar
• Bansal LR, Belair J, Cummings D, Zuccoli G. Late-onset radiation-induced vasculopathy and stroke in a child with medulloblastoma. J Child Neurol. 2015;30(6):800–802. doi:10.1177/088307381453850125015672
   PubMed Web of Science ®Google Scholar
• Benson PJ, Sung JH. Cerebral aneurysms following radiotherapy for medulloblastoma. J Neurosurg. 1989;70(4):545–550. doi:10.3171/jns.1989.70.4.05452926494
   PubMed Web of Science ®Google Scholar
• Neglia JP, Robison LL, Stovall M, et al. New primary neoplasms of the central nervous system in survivors of childhood cancer: a report from the childhood cancer survivor study. J Natl Cancer Inst. 2006;98(21):1528–1537. doi:10.1093/jnci/djj41117077355
   PubMedGoogle Scholar
• Ullrich NJ, Pomeroy SL. Molecular genetics of pediatric central nervous system tumors. Curr Oncol Rep. 2006;8(6):423–429. doi:10.1007/s11912-006-0070-017040620
   PubMedGoogle Scholar
• Wang X, Dubuc AM, Ramaswamy V, et al. Medulloblastoma subgroups remain stable across primary and metastatic compartments. Acta Neuropathol. 2015;129(3):449–457. doi:10.1007/s00401-015-1389-025689980
   PubMed Web of Science ®Google Scholar
• Morrissy AS, Garzia L, Shih DJ, et al. Divergent clonal selection dominates medulloblastoma at recurrence. Nature. 2016;529(7586):351–357. doi:10.1038/nature1647826760213
   PubMed Web of Science ®Google Scholar
• Wang J, Garancher A, Ramaswamy V, Wechsler-Reya RJ. Medulloblastoma: from molecular subgroups to molecular targeted therapies. Annu Rev Neurosci. 2018;41(1):207–232. doi:10.1146/annurev-neuro-070815-01383829641939
   PubMed Web of Science ®Google Scholar
• Das A, McDonald D, Lowe S, et al. Immunological low-dose radiation modulates the pediatric medulloblastoma antigens and enhances antibody-dependent cellular cytotoxicity. Childs Nerv Syst. 2017;33(3):429–436. doi:10.1007/s00381-016-3305-x27942918
   PubMed Web of Science ®Google Scholar
• Li K, Duan WC, Zhao HB, et al. Preoperative neutrophil to lymphocyte ratio and platelet to lymphocyte ratio are associated with the prognosis of group 3 and group 4 medulloblastoma. Sci Rep. 2019;9(1):13239. doi:10.1038/s41598-019-49733-631519974
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. doi:10.1016/j.cell.2011.02.01321376230
   PubMed Web of Science ®Google Scholar
• Jahnisch H, Fussel S, Kiessling A, et al. Dendritic cell-based immunotherapy for prostate cancer. Clin Dev Immunol. 2010;2010:517493. doi:10.1155/2010/51749321076523
   PubMedGoogle Scholar
• Wang SS, Bandopadhayay P, Jenkins MR. Towards immunotherapy for pediatric brain tumors. Trends Immunol. 2019;40(8):748–761. doi:10.1016/j.it.2019.05.00931229353
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411–422. doi:10.1056/NEJMoa100129420818862
   PubMed Web of Science ®Google Scholar
• Holtkamp S, Kreiter S, Selmi A, et al. Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. Blood. 2006;108(13):4009–4017. doi:10.1182/blood-2006-04-01502416940422
   PubMed Web of Science ®Google Scholar
• Kranz LM, Diken M, Haas H, et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature. 2016;534(7607):396–401. doi:10.1038/nature1830027281205
   PubMed Web of Science ®Google Scholar
• Kreiter S, Selmi A, Diken M, et al. Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. Cancer Res. 2010;70(22):9031–9040. doi:10.1158/0008-5472.CAN-10-069921045153
   PubMed Web of Science ®Google Scholar
• Coban C, Kobiyama K, Aoshi T, et al. Novel strategies to improve DNA vaccine immunogenicity. Curr Gene Ther. 2011;11(6):479–484. doi:10.2174/15665231179819281522023477
   PubMed Web of Science ®Google Scholar
• Nair SK, Driscoll T, Boczkowski D, et al. Ex vivo generation of dendritic cells from cryopreserved, post-induction chemotherapy, mobilized leukapheresis from pediatric patients with medulloblastoma. J Neurooncol. 2015;125(1):65–74. doi:10.1007/s11060-015-1890-226311248
   PubMed Web of Science ®Google Scholar
• Majd N, Penas-Prado M. Updates on management of adult medulloblastoma. Curr Treat Options Oncol. 2019;20(8):64. doi:10.1007/s11864-019-0663-031236711
   PubMed Web of Science ®Google Scholar
• Ardon H, De Vleeschouwer S, Van Calenbergh F, et al. Adjuvant dendritic cell-based tumour vaccination for children with malignant brain tumours. Pediatr Blood Cancer. 2010;54(4):519–525. doi:10.1002/pbc.2231919852061
   PubMed Web of Science ®Google Scholar
• Sampson JH, Archer GE, Mitchell DA, et al. An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Mol Cancer Ther. 2009;8(10):2773–2779. doi:10.1158/1535-7163.MCT-09-012419825799
   PubMed Web of Science ®Google Scholar
• Kim W, Liau LM. Dendritic cell vaccines for brain tumors. Neurosurg Clin N Am. 2010;21(1):139–157. doi:10.1016/j.nec.2009.09.00519944973
   PubMed Web of Science ®Google Scholar
• Liau LM, Black KL, Martin NA, et al. Treatment of a patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides: case report. Neurosurg Focus. 2000;9(6):e8. doi:10.3171/foc.2000.9.6.9
   PubMedGoogle Scholar
• Liau LM, Prins RM, Kiertscher SM, et al. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res. 2005;11(15):5515–5525. doi:10.1158/1078-0432.CCR-05-046416061868
   PubMed Web of Science ®Google Scholar
• Heimberger AB, Archer GE, Crotty LE, et al. Dendritic cells pulsed with a tumor-specific peptide induce long-lasting immunity and are effective against murine intracerebral melanoma. Neurosurgery. 2002;50(1):158–164; discussion 164–156. doi:10.1097/00006123-200201000-00024
   Web of Science ®Google Scholar
• Felsberg J, Hentschel B, Kaulich K, et al. Epidermal Growth Factor Receptor Variant III (EGFRvIII) positivity in EGFR-amplified glioblastomas: prognostic role and comparison between primary and recurrent tumors. Clin Cancer Res. 2017;23(22):6846–6855. doi:10.1158/1078-0432.CCR-17-089028855349
   PubMed Web of Science ®Google Scholar
• van den Bent MJ, Gao Y, Kerkhof M, et al. Changes in the EGFR amplification and EGFRvIII expression between paired primary and recurrent glioblastomas. Neuro Oncol. 2015;17(7):935–941. doi:10.1093/neuonc/nov01325691693
   PubMed Web of Science ®Google Scholar
• Aurelian L. Oncolytic viruses as immunotherapy: progress and remaining challenges. Onco Targets Ther. 2016;9:2627–2637. doi:10.2147/OTT.S6304927226725
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov. 2015;14(9):642–662. doi:10.1038/nrd466326323545
   PubMed Web of Science ®Google Scholar
• Killock D. Skin cancer: T-VEC oncolytic viral therapy shows promise in melanoma. Nat Rev Clin Oncol. 2015;12(8):438. doi:10.1038/nrclinonc.2015.10626077044
   PubMed Web of Science ®Google Scholar
• Kohlhapp FJ, Kaufman HL. Molecular pathways: mechanism of action for talimogene laherparepvec, a new oncolytic virus immunotherapy. Clin Cancer Res. 2016;22(5):1048–1054. doi:10.1158/1078-0432.CCR-15-266726719429
   PubMed Web of Science ®Google Scholar
• Kanerva A, Nokisalmi P, Diaconu I, et al. Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus. Clin Cancer Res. 2013;19(10):2734–2744. doi:10.1158/1078-0432.CCR-12-254623493351
   PubMed Web of Science ®Google Scholar
• Yu YA, Galanis C, Woo Y, et al. Regression of human pancreatic tumor xenografts in mice after a single systemic injection of recombinant vaccinia virus GLV-1h68. Mol Cancer Ther. 2009;8(1):141–151.19139123
   PubMed Web of Science ®Google Scholar
• Saha D, Martuza RL, Rabkin SD. Macrophage polarization contributes to glioblastoma eradication by combination immunovirotherapy and immune checkpoint blockade. Cancer Cell. 2017;32(2):253–267 e255. doi:10.1016/j.ccell.2017.07.00628810147
   PubMed Web of Science ®Google Scholar
• Lang FF, Conrad C, Gomez-Manzano C, et al. Phase I study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma. J Clin Oncol. 2018;36(14):1419–1427. doi:10.1200/JCO.2017.75.821929432077
   PubMed Web of Science ®Google Scholar
• Thompson EM, Brown M, Dobrikova E, et al. Poliovirus receptor (CD155) expression in pediatric brain tumors mediates oncolysis of medulloblastoma and pleomorphic xanthoastrocytoma. J Neuropathol Exp Neurol. 2018;77(8):696–702. doi:10.1093/jnen/nly04529878245
   PubMed Web of Science ®Google Scholar
• Hortal AM, Vermeulen JF, Van Hecke W, Bovenschen N. Oncogenic role of cytomegalovirus in medulloblastoma? Cancer Lett. 2017;408:55–59. doi:10.1016/j.canlet.2017.08.02428844716
   PubMed Web of Science ®Google Scholar
• Cinatl J Jr, Cinatl J, Vogel JU, Rabenau H, Kornhuber B, Doerr HW. Modulatory effects of human cytomegalovirus infection on malignant properties of cancer cells. Intervirology. 1996;39(4):259–269. doi:10.1159/0001505279078467
   PubMed Web of Science ®Google Scholar
• Michaelis M, Baumgarten P, Mittelbronn M, Driever PH, Doerr HW, Cinatl J Jr. Oncomodulation by human cytomegalovirus: novel clinical findings open new roads. Med Microbiol Immunol. 2011;200(1):1–5. doi:10.1007/s00430-010-0177-720967552
   PubMed Web of Science ®Google Scholar
• Baryawno N, Sveinbjornsson B, Eksborg S, et al. Tumor-growth-promoting cyclooxygenase-2 prostaglandin E2 pathway provides medulloblastoma therapeutic targets. Neuro Oncol. 2008;10(5):661–674. doi:10.1215/15228517-2008-03518715952
   PubMed Web of Science ®Google Scholar
• Taher C, Frisk G, Fuentes S, et al. High prevalence of human cytomegalovirus in brain metastases of patients with primary breast and colorectal cancers. Transl Oncol. 2014;7(6):732–740. doi:10.1016/j.tranon.2014.09.00825500083
   PubMed Web of Science ®Google Scholar
• Baryawno N, Rahbar A, Wolmer-Solberg N, et al. Detection of human cytomegalovirus in medulloblastomas reveals a potential therapeutic target. J Clin Invest. 2011;121(10):4043–4055. doi:10.1172/JCI5714721946257
   PubMed Web of Science ®Google Scholar
• Yang MY, Lee HT, Chen CM, Shen CC, Ma HI. Celecoxib suppresses the phosphorylation of STAT3 protein and can enhance the radiosensitivity of medulloblastoma-derived cancer stem-like cells. Int J Mol Sci. 2014;15(6):11013–11029. doi:10.3390/ijms15061101324945311
   PubMed Web of Science ®Google Scholar
• Raso A, Mascelli S, Biassoni R, et al. High levels of PROM1 (CD133) transcript are a potential predictor of poor prognosis in medulloblastoma. Neuro Oncol. 2011;13(5):500–508. doi:10.1093/neuonc/nor02221486962
   PubMed Web of Science ®Google Scholar
• Hwang K, Koh EJ, Choi EJ, et al. PD-1/PD-L1 and immune-related gene expression pattern in pediatric malignant brain tumors: clinical correlation with survival data in Korean population. J Neurooncol. 2018;139(2):281–291. doi:10.1007/s11060-018-2886-529730815
   PubMed Web of Science ®Google Scholar
• Vermeulen JF, Van Hecke W, Adriaansen EJM, et al. Prognostic relevance of tumor-infiltrating lymphocytes and immune checkpoints in pediatric medulloblastoma. Oncoimmunology. 2018;7(3):e1398877. doi:10.1080/2162402X.2017.139887729399402
   PubMed Web of Science ®Google Scholar
• Martin AM, Nirschl CJ, Polanczyk MJ, et al. PD-L1 expression in medulloblastoma: an evaluation by subgroup. Oncotarget. 2018;9(27):19177–19191. doi:10.18632/oncotarget.2495129721192
   PubMedGoogle Scholar
• Flores CT, Wildes TJ, Drake JA, et al. Lin(-)CCR2(+) hematopoietic stem and progenitor cells overcome resistance to PD-1 blockade. Nat Commun. 2018;9(1):4313. doi:10.1038/s41467-018-06182-530333482
   PubMed Web of Science ®Google Scholar
• Omuro A, Vlahovic G, Lim M, et al. Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143. Neuro Oncol. 2018;20(5):674–686. doi:10.1093/neuonc/nox20829106665
   PubMed Web of Science ®Google Scholar
• Castriconi R, Dondero A, Negri F, et al. Both CD133+ and CD133– medulloblastoma cell lines express ligands for triggering NK receptors and are susceptible to NK-mediated cytotoxicity. Eur J Immunol. 2007;37(11):3190–3196. doi:10.1002/eji.20073754617918205
   PubMed Web of Science ®Google Scholar
• Fernandez L, Portugal R, Valentin J, et al. In vitro natural killer cell immunotherapy for medulloblastoma. Front Oncol. 2013;3:94. doi:10.3389/fonc.2013.0009423626949
   PubMedGoogle Scholar
• Yvon ES, Burga R, Powell A, et al. Cord blood natural killer cells expressing a dominant negative TGF-beta receptor: implications for adoptive immunotherapy for glioblastoma. Cytotherapy. 2017;19(3):408–418. doi:10.1016/j.jcyt.2016.12.00528109751
   PubMed Web of Science ®Google Scholar
• Vivier E, Raulet DH, Moretta A, et al. Innate or adaptive immunity? The example of natural killer cells. Science. 2011;331(6013):44–49. doi:10.1126/science.119868721212348
   PubMed Web of Science ®Google Scholar
• Liu D, Song L, Brawley VS, et al. Medulloblastoma expresses CD1d and can be targeted for immunotherapy with NKT cells. Clin Immunol. 2013;149(1):55–64. doi:10.1016/j.clim.2013.06.00523891738
   PubMed Web of Science ®Google Scholar
• George RE, Loudon WG, Moser RP, Bruner JM, Steck PA, Grimm EA. In vitro cytolysis of primitive neuroectodermal tumors of the posterior fossa (medulloblastoma) by lymphokine-activated killer cells. J Neurosurg. 1988;69(3):403–409. doi:10.3171/jns.1988.69.3.04033261328
   PubMed Web of Science ®Google Scholar
• Okamoto Y, Shimizu K, Tamura K, et al. An adoptive immunotherapy of patients with medulloblastoma by lymphokine-activated killer cells (LAK). Acta Neurochir (Wien). 1988;94(1–2):47–52. doi:10.1007/BF014066153177046
   PubMed Web of Science ®Google Scholar
• Kang SG, Ryu CH, Jeun SS, et al. Lymphokine activated killer cells from umbilical cord blood show higher antitumor effect against anaplastic astrocytoma cell line (U87) and medulloblastoma cell line (TE671) than lymphokine activated killer cells from peripheral blood. Childs Nerv Syst. 2004;20(3):154–162. doi:10.1007/s00381-003-0898-714968374
   PubMed Web of Science ®Google Scholar
• Shimizu H, Sasaki K, Takaue Y, Ota S, Fzjimoto T. Studies of children with acute lymphoblastic leukemia (ALL) who relapsed. Relationship of site of relapse, time and prognosis. Rinsho Ketsueki. 1989;30(7):999–1004.2810802
   PubMedGoogle Scholar
• Sankhla SK, Nadkarni JS, Bhagwati SN. Adoptive immunotherapy using lymphokine-activated killer (LAK) cells and interleukin-2 for recurrent malignant primary brain tumors. J Neurooncol. 1996;27(2):133–140. doi:10.1007/BF001774768699235
   PubMed Web of Science ®Google Scholar
• Salmaggi A, Dufour A, Silvani A, Ciusani E, Nespolo A, Boiardi A. Immunological fluctuations during intrathecal immunotherapy in three patients affected by CNS tumours disseminating via CSF. Int J Neurosci. 1994;77(1–2):117–125. doi:10.3109/002074594089860247989157
   PubMedGoogle Scholar
• Garfall AL, Maus MV, Hwang WT, et al. Chimeric antigen receptor T cells against CD19 for multiple myeloma. N Engl J Med. 2015;373(11):1040–1047. doi:10.1056/NEJMoa150454226352815
   PubMed Web of Science ®Google Scholar
• Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509–1518. doi:10.1056/NEJMoa121513423527958
   PubMed Web of Science ®Google Scholar
• Kalos M, Levine BL, Porter DL, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011;3(95):95ra73. doi:10.1126/scitranslmed.3002842
   PubMed Web of Science ®Google Scholar
• Louis CU, Savoldo B, Dotti G, et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood. 2011;118(23):6050–6056. doi:10.1182/blood-2011-05-35444921984804
   PubMed Web of Science ®Google Scholar
• Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507–1517. doi:10.1056/NEJMoa140722225317870
   PubMed Web of Science ®Google Scholar
• Porter DL, Hwang WT, Frey NV, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med. 2015;7(303):303ra139. doi:10.1126/scitranslmed.aac5415
   PubMed Web of Science ®Google Scholar
• Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci U S A. 1989;86(24):10024–10028. doi:10.1073/pnas.86.24.100242513569
   PubMed Web of Science ®Google Scholar
• Sadelain M, Brentjens R, Riviere I. The basic principles of chimeric antigen receptor design. Cancer Discov. 2013;3(4):388–398. doi:10.1158/2159-8290.CD-12-054823550147
   PubMed Web of Science ®Google Scholar
• June CH, O’Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018;359(6382):1361–1365. doi:10.1126/science.aar671129567707
   PubMed Web of Science ®Google Scholar
• Brown CE, Alizadeh D, Starr R, et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N Engl J Med. 2016;375(26):2561–2569. doi:10.1056/NEJMoa161049728029927
   PubMed Web of Science ®Google Scholar
• Petersen CT, Krenciute G. Next generation CAR T cells for the Immunotherapy of high-grade glioma. Front Oncol. 2019;9:69. doi:10.3389/fonc.2019.0006930863720
   PubMed Web of Science ®Google Scholar
• Chmielewski M, Abken H. TRUCKs: the fourth generation of CARs. Expert Opin Biol Ther. 2015;15(8):1145–1154. doi:10.1517/14712598.2015.104643025985798
   PubMed Web of Science ®Google Scholar
• Ahmed N, Brawley V, Hegde M, et al. HER2-specific chimeric antigen receptor-modified virus-specific T cells for progressive glioblastoma: a phase 1 dose-escalation trial. JAMA Oncol. 2017;3(8):1094–1101. doi:10.1001/jamaoncol.2017.018428426845
   PubMed Web of Science ®Google Scholar
• Nellan A, Rota C, Majzner R, et al. Durable regression of medulloblastoma after regional and intravenous delivery of anti-HER2 chimeric antigen receptor T cells. J Immunother Cancer. 2018;6(1):30. doi:10.1186/s40425-018-0340-z29712574
   PubMed Web of Science ®Google Scholar
• Majzner RG, Theruvath JL, Nellan A, et al. CAR T cells targeting B7-H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors. Clin Cancer Res. 2019;25(8):2560–2574. doi:10.1158/1078-0432.CCR-18-043230655315
   PubMed Web of Science ®Google Scholar
• Tasian SK, Gardner RA. CD19-redirected chimeric antigen receptor-modified T cells: a promising immunotherapy for children and adults with B-cell acute lymphoblastic leukemia (ALL). Ther Adv Hematol. 2015;6(5):228–241. doi:10.1177/204062071558891626425336
   PubMed Web of Science ®Google Scholar
• Bielamowicz K, Fousek K, Byrd TT, et al. Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma. Neuro Oncol. 2018;20(4):506–518. doi:10.1093/neuonc/nox18229016929
   PubMed Web of Science ®Google Scholar
• Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6(224):224ra225. doi:10.1126/scitranslmed.3008226
   Web of Science ®Google Scholar
• Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385(9967):517–528. doi:10.1016/S0140-6736(14)61403-325319501
   PubMed Web of Science ®Google Scholar
• Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439–448. doi:10.1056/NEJMoa170986629385370
   PubMed Web of Science ®Google Scholar
• Reits EA, Hodge JW, Herberts CA, et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med. 2006;203(5):1259–1271. doi:10.1084/jem.2005249416636135
   PubMed Web of Science ®Google Scholar
• Vermeer DW, Spanos WC, Vermeer PD, Bruns AM, Lee KM, Lee JH. Radiation-induced loss of cell surface CD47 enhances immune-mediated clearance of human papillomavirus-positive cancer. Int J Cancer. 2013;133(1):120–129. doi:10.1002/ijc.2801523292955
   PubMed Web of Science ®Google Scholar
• Qian JM, Yu JB, Kluger HM, Chiang VL. Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery. Cancer. 2016;122(19):3051–3058. doi:10.1002/cncr.3013827285122
   PubMed Web of Science ®Google Scholar
• Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage iii non-small-cell lung cancer. N Engl J Med. 2017;377(20):1919–1929. doi:10.1056/NEJMoa170993728885881
   PubMed Web of Science ®Google Scholar
• Shaverdian N, Lisberg AE, Bornazyan K, et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol. 2017;18(7):895–903. doi:10.1016/S1470-2045(17)30380-728551359
   PubMed Web of Science ®Google Scholar
• Blaeschke F, Paul MC, Schuhmann MU, et al. Low mutational load in pediatric medulloblastoma still translates into neoantigens as targets for specific T-cell immunotherapy. Cytotherapy. 2019;21(9):973–986. doi:10.1016/j.jcyt.2019.06.00931351799
   PubMed Web of Science ®Google Scholar
• Hashimoto Y, Penas-Prado M, Zhou S, et al. Rethinking medulloblastoma from a targeted therapeutics perspective. J Neurooncol. 2018;139(3):713–720. doi:10.1007/s11060-018-2917-229869738
   PubMed Web of Science ®Google Scholar
• Orlando D, Miele E, De Angelis B, et al. Adoptive immunotherapy using PRAME-specific T cells in medulloblastoma. Cancer Res. 2018;78(12):3337–3349. doi:10.1158/0008-5472.CAN-17-314029615432
   PubMed Web of Science ®Google Scholar
• Vulcani-Freitas TM, Saba-Silva N, Cappellano A, Cavalheiro S, Toledo SR. PRAME gene expression profile in medulloblastoma. Arq Neuropsiquiatr. 2011;69(1):9–12. doi:10.1590/S0004-282X201100010000321359415
   PubMed Web of Science ®Google Scholar
• Kasuga C, Nakahara Y, Ueda S, et al. Expression of MAGE and GAGE genes in medulloblastoma and modulation of resistance to chemotherapy. Laboratory investigation. J Neurosurg Pediatr. 2008;1(4):305–313. doi:10.3171/PED/2008/1/4/30518377306
   PubMed Web of Science ®Google Scholar
• Oba-Shinjo SM, Caballero OL, Jungbluth AA, et al. Cancer-testis (CT) antigen expression in medulloblastoma. Cancer Immun. 2008;8:7.18426187
   PubMedGoogle Scholar
• Atanackovic D, Altorki NK, Stockert E, et al. Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients. J Immunol. 2004;172(5):3289–3296. doi:10.4049/jimmunol.172.5.328914978137
   PubMed Web of Science ®Google Scholar
• Kim SH, Castro F, Gonzalez D, Maciag PC, Paterson Y, Gravekamp C. Mage-b vaccine delivered by recombinant listeria monocytogenes is highly effective against breast cancer metastases. Br J Cancer. 2008;99(5):741–749. doi:10.1038/sj.bjc.660452618728665
   PubMed Web of Science ®Google Scholar
• Sypniewska RK, Hoflack L, Tarango M, et al. Prevention of metastases with a mage-b DNA vaccine in a mouse breast tumor model: potential for breast cancer therapy. Breast Cancer Res Treat. 2005;91(1):19–28. doi:10.1007/s10549-004-6454-715868428
   PubMed Web of Science ®Google Scholar
• Toh HC, Wang WW, Chia WK, et al. Clinical benefit of allogeneic melanoma cell lysate-pulsed autologous dendritic cell vaccine in MAGE-positive colorectal cancer patients. Clin Cancer Res. 2009;15(24):7726–7736. doi:10.1158/1078-0432.CCR-09-153719996212
   PubMed Web of Science ®Google Scholar
• Gholamin S, Mitra SS, Feroze AH, et al. Disrupting the CD47-SIRPalpha anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors. Sci Transl Med. 2017;9(381). doi:10.1126/scitranslmed.aaf2968
   Web of Science ®Google Scholar
• Snuderl M, Batista A, Kirkpatrick ND, et al. Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma. Cell. 2013;152(5):1065–1076. doi:10.1016/j.cell.2013.01.03623452854
   PubMed Web of Science ®Google Scholar
• Xu J, Erdreich-Epstein A, Gonzalez-Gomez I, et al. Novel cell lines established from pediatric brain tumors. J Neurooncol. 2012;107(2):269–280. doi:10.1007/s11060-011-0756-522120608
   PubMed Web of Science ®Google Scholar
• Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 2018;8(9):1069–1086. doi:10.1158/2159-8290.CD-18-036730115704
   PubMed Web of Science ®Google Scholar
• Weiss WA, Burns MJ, Hackett C, et al. Genetic determinants of malignancy in a mouse model for oligodendroglioma. Cancer Res. 2003;63(7):1589–1595.12670909
   PubMed Web of Science ®Google Scholar
• Pardridge WM. Brain drug development and brain drug targeting. Pharm Res. 2007;24(9):1729–1732. doi:10.1007/s11095-007-9387-017629776
   PubMed Web of Science ®Google Scholar
• Filley AC, Henriquez M, Dey M. Recurrent glioma clinical trial, CheckMate-143: the game is not over yet. Oncotarget. 2017;8(53):91779–91794. doi:10.18632/oncotarget.2158629207684
   PubMedGoogle Scholar
• Margolin K, Ernstoff MS, Hamid O, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, Phase 2 trial. Lancet Oncol. 2012;13(5):459–465. doi:10.1016/S1470-2045(12)70090-622456429
   PubMed Web of Science ®Google Scholar
• Goldberg SB, Gettinger SN, Mahajan A, et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2016;17(7):976–983. doi:10.1016/S1470-2045(16)30053-527267608
   PubMed Web of Science ®Google Scholar
• Tiwary S, Morales JE, Kwiatkowski SC, Lang FF, Rao G, McCarty JH. Metastatic brain tumors disrupt the blood-brain barrier and alter lipid metabolism by inhibiting expression of the endothelial cell fatty acid transporter Mfsd2a. Sci Rep. 2018;8(1):8267. doi:10.1038/s41598-018-26636-629844613
   PubMed Web of Science ®Google Scholar
• Razpotnik R, Novak N, Curin Serbec V, Rajcevic U. Targeting malignant brain tumors with antibodies. Front Immunol. 2017;8:1181. doi:10.3389/fimmu.2017.0118128993773
   PubMed Web of Science ®Google Scholar
• Regina A, Demeule M, Tripathy S, et al. ANG4043, a novel brain-penetrant peptide-mAb conjugate, is efficacious against HER2-positive intracranial tumors in mice. Mol Cancer Ther. 2015;14(1):129–140. doi:10.1158/1535-7163.MCT-14-039925492620
   PubMed Web of Science ®Google Scholar